ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

sosimerasib

Its studies are led by Shanghai Jeyou Pharmaceutical.

Furthest: phase 3, since Sep 13, 20261 company-led study, 1 open or runningNext primary completion: Apr 2029 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai Jeyou Pharmaceutical11 open or runningphase 3since Sep 13, 2026Sep 13, 2026Apr 2029phase 3 · NCT07833202

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Feb 13, 2025Named sosimerasibINNProposed as its International Nonproprietary Name in WHO's List 132
  2. Sep 13, 2026First study: phase 3 study in NSCLCFirst studyNCT07833202 · 416 planned · China

Ahead

  1. Apr 2029Primary completion: phase 3 study in NSCLCNCT07833202

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07833202NSCLC · China3Not yet recruitingApr 2029416

How it is read

Names in the registry

  • “Sosimerasib in combination with IN10018”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.